No photo of Jeffrey Tyner

View Scopus Profile

Jeffrey Tyner

Associate Professor

  • 6482 Citations
  • 39 h-Index
20022020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Jeffrey Tyner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Targeting PTPN11 dependent Hematologic Malignancies

Chang, B. & Tyner, J.

Project: Research project

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML

Druker, B., Tyner, J. & Agarwal, A.

Project: Research project

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies

Druker, B. & Tyner, J.

Project: Research project

Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven Cancer

Tyner, J.

National Institutes of Health

4/1/14 → 2/28/19

Project: Research project

    • ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia

    Tyner, J.

    National Institutes of Health

    9/1/10 → 8/31/16

    Project: Research project

    • Research Output

    Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms

    Joshi, S. K., Qian, K., Bisson, W. H., Watanabe-Smith, K., Huang, A., Bottomly, D., Traer, E., Tyner, J. W., McWeeney, S. K., Davare, M. A., Druker, B. J. & Tognon, C. E., Jun 11 2020, In : Blood. 135, 24, p. 2159-2170 12 p.

    Research output: Contribution to journal › Article

    • ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

    Joshi, S. K., Keck, J. M., Eide, C. A., Bottomly, D., Traer, E., Tyner, J. W., McWeeney, S. K., Tognon, C. E. & Druker, B. J., Oct 1 2020, In : Leukemia. 34, 10, p. 2798-2804 7 p.

    Research output: Contribution to journal › Article

    Open Access

    Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma

    Anderson, A. N., McClanahan, D., Jacobs, J., Jeng, S., Vigoda, M., Blucher, A. S., Zheng, C., Yoo, Y. J., Hale, C., Ouyang, X., Clayburgh, D., Andersen, P., Tyner, J. W., Bar, A., Lucero, O. M., Leitenberger, J. J., McWeeney, S. K. & Kulesz-Martin, M., Aug 2020, In : Cold Spring Harbor Molecular Case Studies. 6, 4, a005439.

    Research output: Contribution to journal › Article

    Open Access

    • Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients

    Rosenberg, M. W., Watanabe-Smith, K., Tyner, J. W., Tognon, C. E., Druker, B. J. & Borate, U., Jul 21 2020, In : Oncotarget. 11, 29, p. 2807-2818 12 p.

    Research output: Contribution to journal › Article

    Open Access

    • Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy

    Stoner, R. C., Press, R. D., Maxson, J. E., Tyner, J. W. & Dao, K. H. T., Jun 1 2020, In : Leukemia. 34, 6, p. 1684-1688 5 p.

    Research output: Contribution to journal › Article